Abstract
Synthetic grafts, namely expanded polytetrafluoroethlene (ePTFE) and poly(ethylene terephthalate) (Dacron), used for cardiovascular bypass surgery are thrombogenic. Lining the inner lumen (“seeding”) of synthetic grafts with endothelial cells (ECs) increases patency rates similar to those of autologous grafts (e.g. saphenous vein). The major drawback with seeding grafts is the retention of cells present on the graft after implantation in vivo, where large portions of cell wash off. Preconditioning the seeded EC monolayer with shear stress has been shown to promote the reorganisation of the EC cytoskeleton and production of extracellular matrix, resulting in higher EC retention after exposure to blood flow. Vascular ECs have a number of essential and complex roles. ECs synthesise and secrete vasoconstrictors, vasodilators, growth factors, fibrinolytic factors, cytokines, adhesion molecules, matrix proteins and mitogens that modulate many physiological processes such as wound healing, haemostasis, vascular remodelling, inflammatory and immune responses. Vascular cells in vivo are exposed to haemodynamic forces created by the pulsatile flow of blood through the vessel. Due to their unique anatomical position, ECs are constantly exposed to shear stress forces and allow the vessel wall to adapt to changes by modulating EC structure and function. This review describes the mainly in vitro and in vivo studies used to define the molecular role haemodynamics have in vascular disease and its usage in developing tissue engineered vascular bypass grafts.
Keywords: Endothelial cells, shear stress, drug delivery, biomaterials, gene expression, patency, intimal hyperplasia
Current Vascular Pharmacology
Title: Haemodynamic Regulation of Gene Expression in Vascular Tissue Engineering
Volume: 9 Issue: 2
Author(s): Dina S. Vara, Geoffrey Punshon, Kevin M. Sales, George Hamilton and Alexander M. Seifalian
Affiliation:
Keywords: Endothelial cells, shear stress, drug delivery, biomaterials, gene expression, patency, intimal hyperplasia
Abstract: Synthetic grafts, namely expanded polytetrafluoroethlene (ePTFE) and poly(ethylene terephthalate) (Dacron), used for cardiovascular bypass surgery are thrombogenic. Lining the inner lumen (“seeding”) of synthetic grafts with endothelial cells (ECs) increases patency rates similar to those of autologous grafts (e.g. saphenous vein). The major drawback with seeding grafts is the retention of cells present on the graft after implantation in vivo, where large portions of cell wash off. Preconditioning the seeded EC monolayer with shear stress has been shown to promote the reorganisation of the EC cytoskeleton and production of extracellular matrix, resulting in higher EC retention after exposure to blood flow. Vascular ECs have a number of essential and complex roles. ECs synthesise and secrete vasoconstrictors, vasodilators, growth factors, fibrinolytic factors, cytokines, adhesion molecules, matrix proteins and mitogens that modulate many physiological processes such as wound healing, haemostasis, vascular remodelling, inflammatory and immune responses. Vascular cells in vivo are exposed to haemodynamic forces created by the pulsatile flow of blood through the vessel. Due to their unique anatomical position, ECs are constantly exposed to shear stress forces and allow the vessel wall to adapt to changes by modulating EC structure and function. This review describes the mainly in vitro and in vivo studies used to define the molecular role haemodynamics have in vascular disease and its usage in developing tissue engineered vascular bypass grafts.
Export Options
About this article
Cite this article as:
S. Vara Dina, Punshon Geoffrey, M. Sales Kevin, Hamilton George and M. Seifalian Alexander, Haemodynamic Regulation of Gene Expression in Vascular Tissue Engineering, Current Vascular Pharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157016111794519390
DOI https://dx.doi.org/10.2174/157016111794519390 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology Inhibitors of Serine Proteinases from Blood Coagulation Cascade - View on Current Developments
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for the Treatment of Retinal and Eye Diseases
CNS & Neurological Disorders - Drug Targets Phosphotyrosine Signaling in Platelets: Lessons for Vascular Thrombosis
Current Drug Targets Preface
Vascular Disease Prevention (Discontinued) HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design White Matter Damage Along the Uncinate Fasciculus Contributes to Cognitive Decline in AD and DLB
Current Alzheimer Research New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors
Current Pharmaceutical Design Recombinant Factor VIIA, its Clinical Properties, and the Tissue Factor Pathway of Coagulation
Mini-Reviews in Medicinal Chemistry Folic Acid, Neurodegenerative and Neuropsychiatric Disease
Current Molecular Medicine The Follow-Up of Dietary Treatment of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease
Current Molecular Medicine Neurotoxicity and Side-Effects of Highly Active Antiretroviral Therapy [HAART] on the Central and Peripheral Nerve System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammatory Biomarkers in Peripheral Artery Disease: Diagnosis, Prognosis, and Therapeutic Challenges
Current Medicinal Chemistry Multiple Roles of Fibroblast Growth Factor 21 in Metabolism
Current Pharmaceutical Design Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Interstitial Lung Disease Associated with Polymyositis-Dermatomyositis
Current Respiratory Medicine Reviews